The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
- PDF / 281,523 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 210 Views
ORIGINAL ARTICLE
The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus Xueyang Zhang 1 & Ran Bai 1 & Yong Jia 2 & Junwei Zong 3 & Yongbo Wang 1 & Yanan Dong 1 Received: 7 January 2020 / Accepted: 29 July 2020 # The Author(s) 2020
Abstract Aims The objective is to investigate the effects of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus. Materials and methods Thirty-two patients with T2DM and NAFLD admitted to the Third Affiliated Hospital of Dalian Medical University from December 2014 to December 2016 were selected, including 11 females and 21 males, aged 39.34 ± 8.54 years old. The patients were given liraglutide on the basis of their original hypoglycemic regimen. Results After 3 months treatment of liraglutide, FPG was reduced from 8.54 ± 2.21 mmol/L to 6.90 ± 1.73 mmol/L. HbA1c was reduced from 9.72 ± 1.95 to 7.78 ± 1.99. WC was reduced from 103.27 ± 9.92 kg to 93.97 ± 8.35 kg. BMI was reduced from 30.56 ± 4.06 kg/m2 to 28.01 ± 3.12 kg/m2. FLI was reduced from 79.23 ± 16.56 to 58.83 ± 19.75. The differences were statistically significant (p < 0.001). TG was reduced from 2.95 ± 2.13 mmol/L to 2.27 ± 1.31 mmol/L. The difference was significant (p < 0.01). Meanwhile, HOMA-IR was reduced from 1.504 ± 0.002 to 1.503 ± 0.002. GGT was reduced from 62.63 ± 71.61 U/L to 38.13 ± 30.13 U/L. AST was reduced from 27.25 ± 13.74 U/L to 25.44 ± 16.69 U/L. The differences were statistically significant (p < 0.05). After treatment, FCP, TC, HDL-C, LDL-C, ALT, and HOMA-β were also improved compared with before treatment, but the difference was not statistically significant (p > 0.05). Conclusion In addition to effectively lowering glucose and improving islet resistance, liraglutide could also improve obesity and adjust blood lipids. However, the improvement of islet function might not be significant after 3 months of treatment. Liraglutide could reduce liver fat accumulation in patients with T2DM and NAFLD. Keywords Liraglutide . Nonalcoholic fatty liver disease . Type 2 diabetes
Introduction The prevalence of diabetes mellitus (DM), especially type 2 diabetes (T2DM), is increasing markedly worldwide, including in China [1]. In 2013, the overall prevalence of DM in Chinese adult population was 10.4% [2]. Insulin resistance is a
* Xueyang Zhang [email protected] * Ran Bai [email protected] 1
Department of Endocrinology, The first affiliated Hospital of Dalian Medical University, Dalian, Liaoning, Dalian, Liaoning, China
2
Institute of Integrative Medicine, Dalian Medical University, Dalian, Liaoning, China
3
Department of Orthopedics, The first affiliated Hospital of Dalian Medical University, Dalian, Liaoning, Dalian, Liaoning, China
metabolic feature of T2DM. Obesity and insulin resistance are key factors in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The progression of NAFLD is due to the accumulation of triglycerides (TG) in the liver. At the same time, there was evidence that the accumulation of TGs in the liver increased syst
Data Loading...
